Newsletter
donate now

Search Results for: Ibrutinib – Page 5

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

January 24, 2023

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues while taking ibrutinib or other Bruton’s tyrosine kinase (BTK) inhibitors.

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

January 24, 2023

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

December 29, 2022

In this interview, Dr. Brian Koffman interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the ALPINE trial, a phase 3 clinical trial directly comparing the efficacy of zanubrutinib vs. ibrutinib in patients with relapsed/refractory CLL / SLL.

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

August 25, 2022

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data of the fixed duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (treatment) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Didn't find what you where looking for?

Try our advanced search page!
Search Now!